var data={"title":"Nivolumab: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nivolumab: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/763492?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">see &quot;Nivolumab: Drug information&quot;</a> and <a href=\"topic.htm?path=nivolumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nivolumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26819875\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Opdivo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45691984\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Opdivo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50189836\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Immune Checkpoint Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50772821\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">see &quot;Nivolumab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Colorectal cancer (CRC), metastatic (microsatellite instability-high or mismatch repair deficient):</b> Children &ge;12 years and Adolescents: IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colorectal cancer, metastatic (microsatellite instability-high or mismatch repair deficient):</b> IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Head and neck cancer, squamous cell, recurrent or metastatic:</b> IV: 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Ferris 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatocellular carcinoma:</b> IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma, classical:</b> IV: 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Ansell 2015; Younes 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Melanoma, unresectable or metastatic:</b> IV: 240 mg once every 2 weeks (as a single agent) until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Melanoma, unresectable or metastatic, first-line combination therapy:</b> IV: 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 doses, followed by 240 mg (flat dose) once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-small cell lung cancer, metastatic, progressive:</b> IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal cell cancer, advanced:</b> IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urothelial carcinoma (locally advanced or metastatic):</b> IV: 240 mg once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>Dosing adjustment for toxicity:</b> Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Withhold treatment for any of the following; may resume treatment upon recovery to grade 0 or 1 toxicity:</i> <b>Note:</b> If receiving combination therapy with ipilimumab, when nivolumab is withheld, ipilimumab should also be withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adrenal insufficiency (grade 2)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Colitis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 2 colitis or diarrhea; for grade 2 colitis with a duration &gt;5 days; also administer systemic corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) followed by a corticosteroid taper; may increase to prednisone 1 to 2 mg/kg/day (or equivalent) if colitis worsens or does not improve despite corticosteroid use</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 3 colitis or diarrhea (single-agent nivolumab); also administer systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diabetes mellitus, type 1 (grade 3 hyperglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Encephalitis (new onset moderate or severe neurologic toxicity)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypophysitis (grade 2 or 3); also administer high-dose systemic corticosteroids (prednisone 1 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pneumonitis (grade 2); also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rash (grade 3), suspected Stevens-Johnson syndrome or toxic epidermal necrolysis; also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other immune-mediated toxicities; also administer high-dose systemic corticosteroids followed by a corticosteroid taper (upon improvement to grade 1 or lower) over at least 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other treatment-related toxicity (severe or grade 3, first occurrence)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Permanently discontinue for:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adrenal insufficiency (grade 3 or 4); also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Colitis or diarrhea (grade 3, if in combination with ipilimumab) or colitis or diarrhea (grade 4); also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Colitis (recurrent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diabetes mellitus, type 1 (grade 4 hyperglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Encephalitis (immune mediated); also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypophysitis (grade 4); also administer high-dose systemic corticosteroids (prednisone 1 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Myocarditis (grade 3); also administer high-dose systemic corticosteroids followed by a corticosteroid taper (upon improvement to grade 1 or lower) over at least 1 month</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pneumonitis (grade 3 or 4); also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rash (grade 4), or confirmed Stevens-Johnson syndrome or toxic epidermal necrolysis; also administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Any toxicity requiring corticosteroid dose of prednisone &ge;10 mg/day (or equivalent) for longer than 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other adverse reactions that are life-threatening or grade 4, severe or grade 3 adverse reactions that recur, or persistent grade 2 or 3 treatment-related toxicity that lasts beyond 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infusion-related reaction:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild or moderate reaction: Interrupt or slow the infusion rate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe or life-threatening reaction: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thyroid disorder (hyperthyroidism or hypothyroidism):</i> There are no recommended dosage modifications. Initiate antithyroid therapy for hyperthyroidism; administer thyroid hormone replacement therapy for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Renal impairment <b>prior to</b> treatment initiation:</i> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Renal toxicity<b> during</b> treatment (nephritis or renal dysfunction):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &gt;1.5 to 6 &times; ULN: Withhold treatment; administer corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) followed by a corticosteroid taper; may resume therapy upon recovery to grade 0 or 1 toxicity. If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 to 2 mg/kg/day (or equivalent).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &gt;6 &times; ULN or life-threatening: Permanently discontinue; initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatic impairment <b>prior to</b> treatment initiation:</i> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild (total bilirubin &le;ULN and AST &gt;ULN or total bilirubin &gt;1 to 1.5 &times; ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 &times; ULN and any AST) impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe (total bilirubin &gt;3 &times; ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity <b>during</b> treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>without</b> hepatocellular carcinoma (HCC): Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Total bilirubin &gt;1.5 to 3 &times; ULN or AST or ALT &gt;3 to 5 &times; ULN: Withhold treatment; may resume therapy upon recovery to grade 0 or 1 toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Total bilirubin &gt;3 &times; ULN or AST or ALT &gt;5 &times; ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>with</b> HCC: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If AST and/or ALT is within normal limits at baseline and increases to &gt;3 to 5 &times; ULN, or if AST and/or ALT is &gt;1 to 3 &times; ULN at baseline and increases to &gt;5 to 10 &times; ULN, or if AST and/or ALT is &gt;3 to 5 &times; ULN at baseline and increases to &gt;8 to 10 &times; ULN: Withhold treatment; may resume therapy upon recovery to baseline</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If AST or ALT increases to &gt;10 &times; ULN or total bilirubin increases to &gt;3 &times; ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immune-mediated hepatitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>without</b> HCC: Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 2 transaminase elevations (with or without total bilirubin elevations): Withhold treatment and initiate high-dose systemic corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe (grade 3) or life-threatening (grade 4) transaminase elevations (with or without bilirubin elevations): Permanently discontinue treatment and initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>with</b> HCC: Adults: Permanently discontinue, withhold, or continue nivolumab based on the severity of immune-mediated hepatitis, changes from baseline ALT and/or AST levels. Administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent followed by a taper) when nivolumab is withheld or discontinued due to immune-mediated hepatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51131234\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline renal impairment:</i> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Renal toxicity<b> during</b> treatment (nephritis or renal dysfunction):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &gt;1.5 to 6 &times; ULN: Withhold treatment; administer corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) followed by a corticosteroid taper; may resume therapy upon recovery to grade 0 or 1 toxicity. If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 to 2 mg/kg/day (or equivalent).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &gt;6 &times; ULN or life-threatening: Permanently discontinue; initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent) followed by a corticosteroid taper.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51131235\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline hepatic impairment:</i> Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild (total bilirubin &le;ULN and AST &gt;ULN or total bilirubin &gt;1 to 1.5 &times; ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 &times; ULN and any AST) impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe (total bilirubin &gt;3 &times; ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity <b>during</b> treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>without</b> hepatocellular carcinoma (HCC): Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Total bilirubin &gt;1.5 to 3 &times; ULN or AST or ALT &gt;3 to 5 &times; ULN: Withhold treatment; may resume therapy upon recovery to grade 0 or 1 toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Total bilirubin &gt;3 &times; ULN or AST or ALT &gt;5 &times; ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immune-mediated hepatitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>without</b> HCC: Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 2 transaminase elevations (with or without total bilirubin elevations): Withhold treatment and initiate high-dose systemic corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe (grade 3) or life-threatening (grade 4) transaminase elevations (with or without bilirubin elevations): Permanently discontinue treatment and initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26827910\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">see &quot;Nivolumab: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic (microsatellite instability-high or mismatch repair deficient):</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Overman 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer, squamous cell, recurrent or metastatic:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Ferris 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatocellular carcinoma:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks (as a single agent) until disease progression or unacceptable toxicity (El-Khoueiry 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma, classical:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Ansell 2015; Younes 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, adjuvant treatment: </b>IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or</b> 480 <b>mg </b>(flat dose) once every 4 weeks until disease recurrence or unacceptable toxicity for up to 1 year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year (Weber 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, unresectable or metastatic:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 mg (flat dose) once every 4 weeks (as a single agent) until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks (as a single agent) until disease progression or unacceptable toxicity (Robert 2015; Weber 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, unresectable or metastatic, first-line combination therapy:</b> IV: 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 doses, followed by 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg</b> (flat dose) once every 4 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. <b>Note:</b> If nivolumab therapy is withheld, ipilimumab should also be withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 doses, followed by 3 <b>mg/kg</b> once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity (Larkin 2015; Wolchok 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer, metastatic, progressive:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Borghaei 2015; Brahmer 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell cancer, advanced:</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing: </i>3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Motzer 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urothelial carcinoma (locally advanced or metastatic):</b> IV: 240 <b>mg</b> (flat dose) once every 2 weeks <b>or </b>480 <b>mg </b>(flat dose) once every 4 weeks until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Sharma 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Small cell lung cancer, progressive (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single agent:</i> IV: 3 <b>mg/kg</b> once every 2 weeks until disease progression or unacceptable toxicity (Antonia 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy:</i> IV: 1 <b>mg/kg</b> once every 3 weeks (in combination with ipilimumab) for 4 doses, followed by 3 <b>mg/kg</b> once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity (Antonia 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991167\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal impairment <b>prior to</b> treatment initiation: </i>No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal toxicity</i>\n      <b>\n        <i> during</i></b>\n      <i> treatment  (nephritis or renal dysfunction): </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creatinine &gt;1.5 to 6 &times; ULN: Withhold treatment; administer corticosteroids (prednisone 0.5 to 1 mg/kg daily or equivalent) followed by a corticosteroid taper; may resume therapy upon recovery to grade 0 or 1 toxicity. If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 to 2 mg/kg daily (or equivalent).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creatinine &gt;6 &times; ULN or life-threatening: Permanently discontinue; initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent) followed by a corticosteroid taper.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988530\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment <b>prior to</b> treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 &times; ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 &times; ULN and any AST) impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe (total bilirubin &gt;3 &times; ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity</i>\n      <b>\n        <i> during</i></b>\n      <i> treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients <b>without</b> hepatocellular carcinoma (HCC):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST or ALT &gt;3 to 5 &times; ULN or total bilirubin &gt;1.5 to 3 &times; ULN: Withhold treatment; may resume therapy upon recovery to grade 0 or 1 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST or ALT &gt;5 &times; ULN or total bilirubin &gt;3 &times; ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients <b>with</b> HCC:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If AST and/or ALT is within normal limits at baseline and increases to &gt;3 to 5 &times; ULN, <b>or</b> if AST and/or ALT is &gt;1 to 3 &times; ULN at baseline and increases to &gt;5 to 10 &times; ULN, <b>or</b> if AST and/or ALT is &gt;3 to 5 &times; ULN at baseline and increases to &gt;8 to 10 &times; ULN: Withhold treatment; may resume therapy upon recovery to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If AST or ALT increases to &gt;10 &times; ULN or total bilirubin increases to &gt;3 &times; ULN: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune-mediated hepatitis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>without</b> HCC:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Grade 2 transaminase elevations (with or without total bilirubin elevations): Withhold treatment and initiate high-dose systemic corticosteroids (prednisone 0.5 to 1 mg/kg daily or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe (grade 3) or life-threatening (grade 4) transaminase elevations (with or without bilirubin elevations): Permanently discontinue treatment and initiate high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients <b>with</b> HCC: Permanently discontinue, withhold, or continue nivolumab based on the severity of immune-mediated hepatitis, changes from baseline ALT and/or AST levels. Administer high-dose systemic corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent followed by a taper) when nivolumab is withheld or discontinued due to immune-mediated hepatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26819876\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Opdivo: 40 mg/4 mL (4 mL); 100 mg/10 mL (10 mL); 240 mg/24 mL (24 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26819874\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27369132\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s048s049s050s051s052s061s062s064s065s066lbl.pdf#page=71&amp;token=YahzR4o0yHkSsdQ+McbNkSwpA5f6qoQFWd++M91td2enkWwr5e20aqE219R8oUPPaUztGZsUlAbCSsAT+zk6k+T2emEN2Qj+YxsHDRr7htbagC38lZZBCBH0QeYd/1/9vuMm6mQDvyzaH7hcWokeIw==&amp;TOPIC_ID=115765\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s048s049s050s051s052s061s062s064s065s066lbl.pdf#page=71</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50189840\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as an IV infusion over 60 minutes through a line with a sterile, nonpyrogenic, low protein binding 0.2 to 1.2 micrometer in-line filter. Do not administer other medications through the same IV line. Flush IV line at the end of the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with ipilimumab:</i> When administered in combination with ipilimumab, infuse nivolumab first followed by ipilimumab on the same day. Use separate infusion bags and filters for each infusion. If nivolumab therapy is withheld, ipilimumab should also be withheld.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26822038\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Do not shake. After preparation in NS or D5W, store the infusion solution at room temperature for no more than 8 hours (including infusion time) or refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours (including infusion time). Infusion must be completed within 24 hours of preparation. Do not freeze solutions prepared for infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50189837\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan (FDA approved in ages &ge;12 years and adults); treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients with disease progression on or after platinum-based therapy (FDA approved in adults); treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib (FDA approved in adults); treatment of classical Hodgkin lymphoma (cHL) in patients that have relapsed or progressed following autologous hematopoietic stem cell transplant (HSCT) and brentuximab vedotin, or three or more lines of systemic therapy that includes autologous HSCT (FDA approved in adults); treatment (as a single agent) of BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma (FDA approved in adults); treatment of unresectable or metastatic melanoma (in combination with ipilimumab) (FDA approved in adults); treatment of metastatic non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy (in patients with EGFR or ALK genomic tumor aberrations should have disease progression [on approved EGFR- or ALK-directed therapy] prior to receiving nivolumab) (FDA approved in adults); treatment of advanced renal cell cancer in patients who have received prior anti-angiogenic therapy (FDA approved in adults); treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression during or following a platinum-containing therapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing therapy (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27560227\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nivolumab may be confused with atezolizumab, avelumab, durvalumab, necitumumab, pembrolizumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27160903\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Cardiovascular: Edema, peripheral edema, pulmonary embolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache, malaise, migraine, neuritis, peripheral nerve palsy (peroneal), peripheral neuropathy (new onset and exacerberations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, palmar-plantar erythrodysesthesia, pruritus, skin rash (less common with immune-mediated), vitiligo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenocortical insufficiency (including immune-mediated events), hypercalcemia, hyperglycemia, hyperkalemia, hyperthyroidism (including immune-mediated events), hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypothyroidism (including immune-mediated events), increased gamma-glutamyl transferase, increased serum cholesterol, increased serum triglycerides, thyroiditis (including immune-mediated events), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, colitis (including immune-mediated events), constipation, decreased appetite, diarrhea, increased serum amylase, increased serum lipase, intestinal perforation, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia, lymphocytopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis (immune-mediated), increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (no evidence of altered pharmacokinetic profile), graft versus host disease (more common within 14 days of stem cell infusion), Sjogren syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, musculoskeletal pain, myopathy, rheumatic disease (spondyloarthropathy), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, increased serum creatinine, nephritis (immune-mediated), renal insufficiency (immune-mediated)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchopneumonia, cough (includes productive cough), dyspnea (includes exertional dyspnea), interstitial pulmonary disease, nasal congestion, pleural effusion, pneumonia, pneumonitis (including immune-mediated events), respiratory failure, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Febrile reaction (events without an infectious cause that required steroids), fever (may include tumor-associated fever), infusion related reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Demyelinating disease (immune-mediated), diabetic ketoacidosis, duodenitis (immune-mediated), encephalitis (limbic/lymphocytic/viral; may be immune-mediated), facial paralysis (immune-mediated), gastritis (immune-mediated), Guillain-Barr&eacute; syndrome (immune-mediated), hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hypophysitis (including immune-mediated events), iritis (immune-mediated), lymphadenitis (immune-mediated; histiocytic necrotizing lymphadenitis [Kikuchi lymphadenitis]), motor dysfunction (immune-mediated), myasthenia (myasthenic syndrome; immune-mediated), myocarditis (immune-mediated), myositis (immune-mediated), neuropathy (autoimmune; immune-mediated), pancreatitis (immune-mediated), pituitary insufficiency (immune-mediated), pneumonia due to <i>Pneumocystis carinii</i>, polymyalgia rheumatica (immune-mediated), rhabdomyolysis (immune-mediated), sarcoidosis (immune-mediated), sepsis (systemic inflammatory response), sixth nerve palsy (abducens nerve palsy; immune-mediated), type I diabetes mellitus (immune-mediated event), uveitis (immune-mediated), vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26702130\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to nivolumab or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821961\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Adrenal insufficiency may occur; may require hormone replacement therapy and/or corticosteroid therapy. The median time to onset across several clinical trials was 3 to 4.3 months (range: 15 days to 21 months). In studies, the median duration of high-dose systemic corticosteroid therapy was 9 to 11 days (range: 1 day to 2.7 months). Monitor for signs/symptoms of adrenal insufficiency both during and after treatment. Administer corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent followed by a taper) for severe (grade 3) or life-threatening (grade 4) adrenal insufficiency. Withhold nivolumab for moderate (grade 2) and permanently discontinue for severe (grade 3) or life-threatening (grade 4) toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Immune-mediated rash, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been observed in patients receiving nivolumab; some cases have been fatal. The median time to onset of immune-mediated rash ranged was 18 days to 2.8 months (range: 1 day to 25.8 months) after nivolumab initiation. Withhold treatment for signs or symptoms of SJS or TEN and refer to specialist for assessment and treatment; discontinue permanently if confirmed. Withhold treatment for grade 3 rash and permanently discontinue for life-threatening (grade 4) rash and administer corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent followed by a taper) for severe (grade 3) or life-threatening (grade 4) immune-mediated rash. High-dose systemic corticosteroids (followed by a corticosteroid taper) were administered to some patients for a median duration of 12 to 14 days (range: 1 day to 9 months); topical corticosteroids were also used to manage dermatologic toxicity. Complete resolution occurred in nearly half of patients; some patient experienced recurrence with rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Type 1 diabetes mellitus may occur, including cases of diabetic ketoacidosis. The median time to onset was 2.5 to 4.4 months (range: 15 days to 22 months). Monitor for hyperglycemia. Withhold nivolumab for severe (grade 3) hyperglycemia until blood sugar has been appropriately controlled. Permanently discontinue for life-threatening (grade 4) hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Encephalitis: Immune-mediated encephalitis (without clear etiology) may occur. Withhold nivolumab for new-onset moderate to severe neurologic signs/symptoms; evaluate to rule out other neurologic causes or infection. Evaluate with neurology consultation, brain MRI, and lumbar puncture. For confirmed immune-mediated encephalitis felt to be caused by nivolumab (if other etiologies are ruled out), administer corticosteroids (prednisone 1 to 2 mg/kg/day or equivalent), followed by a corticosteroid taper. Permanently discontinue nivolumab if immune-mediated encephalitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Diarrhea or colitis occurred commonly in patients receiving nivolumab (some cases were fatal). Immune-mediated colitis (defined as no other clear etiology and requiring corticosteroid use), including cases of grades 2 and 3 colitis, occurred in some patients. The median time to onset of colitis was 1.6 to 5.3 months (range: 2 days to 21 months) from nivolumab initiation; some cases developed after nivolumab was discontinued for other reasons. In studies, the median duration of high-dose systemic corticosteroid therapy was 23 days to 1.1 months (range: 1 day to 12 months). Most patients with grade 2 or 3 immune-related colitis had complete resolution (improvement to grade 0); after resolution, nivolumab was reinitiated in some patients without recurrence, although was permanently discontinued in other patients. Monitor for signs and symptoms of colitis. May require treatment interruption, corticosteroid therapy, and/or permanent discontinuation. Severe colitis (grade 3) or life-threatening colitis (grade 4) should be managed with corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent) followed by a corticosteroid taper. Moderate colitis (grade 2) of &gt;5 days duration should be managed with corticosteroids (prednisone 0.5 to 1 mg/kg daily or equivalent) followed by a corticosteroid taper; may increase to prednisone 1 to 2 mg/kg daily (or equivalent) if colitis worsens or does not improve despite corticosteroid therapy. Some cases required the addition of infliximab to corticosteroid therapy. Permanently discontinue nivolumab for grade 4 colitis or diarrhea, or colitis that recurs upon reinitiation (single-agent therapy) or for severe or life-threatening colitis (grade 3 or 4) or for colitis that recurs upon reinitiation (in combination with ipilimumab).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: ALT, AST, alkaline phosphatase, and total bilirubin elevations have occurred in nivolumab-treated patients. Immune-mediated hepatitis (defined as no other clear etiology and requiring corticosteroid use) occurred in patients receiving nivolumab; most cases included grade 2 and grade 3 hepatitis, although grade 4 toxicity also occurred. The median time to onset was 2.1 to 3.3 months (range: 6 days to 11 months) after nivolumab initiation. Immune-mediated hepatitis was managed with high-dose systemic corticosteroids; in some cases, mycophenolate was added to corticosteroid therapy. In studies, the median duration of high-dose systemic corticosteroid therapy was 23 days to 1.1 months (range: 1 day to 13.2 months). Immune-mediated hepatitis resolved and did not recur with continued corticosteroid use in some patients, although some patients experienced recurrence and permanently discontinued treatment. When used in combination with ipilimumab, a majority of patients had complete resolution of hepatitis after completion of steroid therapy, and some patients had recurrence or worsening hepatitis when nivolumab and ipilimumab were restarted. Monitor liver function at baseline and periodically for changes. In patients <b>without</b> hepatocellular carcinoma (HCC), initiate corticosteroids (prednisone 0.5 to 1 mg/kg daily or equivalent for grade 2 or prednisone 1 to 2 mg/kg daily or equivalent followed by a corticosteroid taper for grade 3 or 4) transaminase elevations (with or without total bilirubin elevations). Withhold treatment for moderate (grade 2) immune-mediated hepatitis; permanently discontinue for severe (grade 3) or life-threatening (grade 4) immune-mediated hepatitis. In patients <b>with</b> HCC, administer corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent followed by a taper) when nivolumab is withheld or discontinued due to immune-mediated hepatitis. Permanently discontinue, withhold, or continue nivolumab based on the severity of immune-mediated hepatitis as well as transaminase levels or changes from baseline transaminase levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypophysitis: Hypophysitis may occur; some patients developed grades 1, 2, or 3 toxicity. Most patients received corticosteroids; combination therapy was restarted for the majority of the patients without worsening hypophysitis (several patients continued on corticosteroid therapy). The median time to onset was 2.7 to 4.9 months (range: from 27 days to 11 months). Monitor for signs/symptoms of hypophysitis. Administer hormone replacement therapy as clinically indicated and corticosteroids (prednisone 1 mg/kg/day or equivalent followed by a taper) for grade 2 or higher toxicity. In studies, the median duration of high-dose systemic corticosteroid therapy was 14 to 19 days (range: 1 day to 2 months). Withhold nivolumab for moderate (grade 2) or severe (grade 3) and permanently discontinue treatment for life-threatening (grade 4) hypophysitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Infusion-related reactions have occurred with both single-agent nivolumab and when used in combination with ipilimumab; severe reactions, although rare, were observed when given as a single agent. Monitor closely; discontinue for severe or life-threatening reactions. Mild or moderate reactions may be managed by interrupting or decreasing the infusion rate. A pharmacokinetic study that looked at the safety of a shortened nivolumab infusion time found similar incidences of infusion-related reactions when nivolumab was administered over 60 or 30 minutes. Small percentages of patients receiving the 60-minute or 30-minute infusion experienced reactions within 48 hours of infusion, which resulted in dose delay, permanent discontinuation, or withholding of nivolumab (0.5% and 1.4%, respectively).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Renal dysfunction has occurred with nivolumab therapy. Immune-mediated nephritis (defined as renal dysfunction or &ge; grade 2 creatinine elevations with no other clear etiology and requiring corticosteroid use) or autoimmune nephritis may occur with nivolumab treatment. The median time to onset was 2.7 to 4.6 months (range: 9 days to 12.3 months). For single-agent nivolumab, all patients received high-dose systemic corticosteroids (at least 40 mg prednisone or equivalent per day) for a median duration of 3 weeks (range: 1 day to 15.4 months); complete resolution occurred in about one-half of patients, with no recurrence upon rechallenge. When used in combination with ipilimumab, two-thirds of patients received high-dose systemic corticosteroids (at least 40 mg prednisone or equivalent per day) for a median duration of 2 weeks (range: 1 day to 1.1 months); complete resolution occurred in all patients, some patients resumed combination therapy with no recurrence. Monitor serum creatinine at baseline and periodically during treatment. Initiate corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent) followed by a corticosteroid taper for life-threatening (grade 4) serum creatinine elevation and permanently discontinue nivolumab. Withhold treatment for moderate (grade 2) and severe (grade 3) creatinine elevations and administer corticosteroids (prednisone 0.5 to 1 mg/kg daily or equivalent) followed by a corticosteroid taper; if toxicity worsens or does not improve, increase to prednisone 1 to 2 mg/kg daily (or equivalent).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Uveitis and iritis have been reported. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed in patients receiving nivolumab (as a single agent and in combination with ipilimumab) and may require systemic corticosteroids to reduce the risk of permanent vision loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Nivolumab may cause immune-mediated pneumonitis (severe pneumonitis or interstitial lung disease); fatal cases have been reported. Immune-mediated pneumonitis is defined as no other clear etiology and requiring corticosteroid use. The median time to onset was 1.6 to 3.5 months (range: 1 day to 22.3 months) across several clinical trials. Some cases developed after nivolumab was discontinued for other reasons. High-dose systemic corticosteroids (followed by a corticosteroid taper) were administered for a median duration of 26 to 30 days (range: 1 day to 11.8 months). Most patients improved to grade 0 or 1; some patients with grade 2 or 3 pneumonitis had complete resolution (after completing corticosteroid therapy) and nivolumab was reinitiated without recurrence in some patients. Monitor for signs (with radiographic imaging) and symptoms of pneumonitis. May require treatment interruption, corticosteroid therapy, and/or permanent discontinuation. Grades 2, 3, or 4 pneumonitis should be managed with corticosteroids (prednisone 1 to 2 mg/kg daily or equivalent) followed by a corticosteroid taper. Withhold treatment until resolution for moderate (grade 2) immune-mediated pneumonitis; permanently discontinue for severe (grade 3) or life-threatening (grade 4) immune-mediated pneumonitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Immune-mediated hyperthyroidism and hypothyroidism/thyroiditis have occurred, mostly grades 1 and 2 hyper-/hypothyroidism (one patient receiving nivolumab in combination with ipilimumab experienced grade 3 autoimmune thyroiditis). The median onset for hyperthyroidism was 23 days to 1.5 months (range: 1 day to 14.2 months); most cases resolved (may require medical management, including corticosteroids and methimazole). Hypothyroidism occurred with a median onset of 2 to 3 months (range: 1 day to 16.6 months). Most patients received subsequent nivolumab (with or without ipilimumab) treatment while continuing thyroid replacement therapy. Monitor thyroid function at baseline and for changes periodically during treatment (in one study, patients were evaluated at baseline, treatment day 1, and every 6 weeks). Isolated hypothyroidism may be managed with hormone replacement therapy; initiate medical management (eg, methimazole) to control hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other immune-mediated toxicities: Other clinically relevant and potentially fatal immune-mediated disorders may occur; may develop after discontinuation of nivolumab. Immune-mediated adverse reactions observed included facial/abducens nerve paresis, autoimmune neuropathy, demyelination, duodenitis, gastritis, Guillain-Barr&eacute; syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), hypopituitarism, motor dysfunction, myasthenic syndrome, myocarditis, myositis, pancreatitis, polymyalgia rheumatica, rhabdomyolysis, sarcoidosis, systemic inflammatory response syndrome, and vasculitis. If an immune-mediated adverse event is suspected, evaluate to exclude other causes. Based on symptom severity, withhold or permanently discontinue nivolumab, administer high-dose corticosteroids, and if appropriate, initiate hormone-replacement therapy. Upon improvement to grade 0 or 1, begin corticosteroid taper (over at least 1 month). After corticosteroid taper is completed and based on the severity of the reaction, may consider reinitiating nivolumab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorders: Anti-PD-1 monoclonal antibodies generate an immune response that may aggravate underlying autoimmune disorders or prior immune-related adverse events. A retrospective study analyzed the safety and efficacy of treatment with anti-PD-1 monoclonal antibodies (eg, nivolumab or pembrolizumab) in melanoma patients with preexisting autoimmune disease or prior significant ipilimumab-mediated adverse immune events. Results showed that while immune toxicities associated with this class of therapy did occur, most reactions were mild and easily manageable, and did not require permanent drug therapy discontinuation. A significant percentage of patients achieved clinical response with anti-PD-1 monoclonal antibody therapy, despite baseline autoimmunity or prior ipilimumab-related adverse events (Menzies 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematopoietic stem cell transplant: Patients who received allogeneic hematopoietic stem cell transplant (HSCT) following discontinuation of nivolumab therapy experienced complications (some fatal) including severe or refractory acute graft versus host disease (some cases occurring within 14 days after stem cell infusion), noninfectious febrile syndrome (requiring corticosteroids), lymphocytic encephalitis, viral encephalitis, and sinusoidal obstructive syndrome (SOS; formerly called veno-occlusive disease). These complications may occur despite intervening therapy between nivolumab and HSCT. Monitor closely for early signs/symptoms of transplant-related complications and manage promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26736581\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26736578\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=115765&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Nivolumab.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821958\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Nivolumab may be expected to cross the placenta; effects to the fetus may be greater in the second and third trimesters. Based on its mechanism of action, nivolumab is expected to cause fetal harm if used during pregnancy. Women of reproductive potential should use highly effective contraception during therapy and for at least 5 months after the last nivolumab dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50189841\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic and renal function tests (baseline and periodic), thyroid function (baseline and periodically [eg, at treatment day 1 and every 6 weeks]); blood glucose. Monitor for signs/symptoms of adrenal insufficiency, hypophysitis, thyroid disorders, immune-mediated colitis, pneumonitis, rash/dermatologic toxicity, encephalitis (changes in neurologic function); monitor for infusion reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26822041\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor to block  the ligands PD-L1 and PD-L2 from binding. The negative PD-1 receptor signaling that regulates T-cell activation and proliferation is therefore disrupted (Robert 2015). This releases PD-1 pathway-mediated inhibition of the immune response, including the antitumor immune response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) results in enhanced T-cell function that is greater than that of either antibody alone, resulting in improved anti-tumor responses in metastatic melanoma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26822043\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 6.8 L (single-agent); ~8 L (combination therapy with ipilimumab); the predicted exposure after a 30-minute infusion is comparable to that seen with a 60-minute infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~25 days (single-agent and combination therapy with ipilimumab)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26844488\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Opdivo Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/4 mL (4 mL): $1,240.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $3,100.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240MG/24ML (24 mL): $7,439.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26732989\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Opdivo (AT, CZ, DK, ES, FR, GB, HK, HU, IE, IL, IS, JP, KR, LT, LU, NL, NO, PL, PT, SA, SG, SK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. <i>N Engl J Med</i>. 2015;372(4):311-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/25482239/pubmed\" target=\"_blank\" id=\"25482239\">25482239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27718784\"></a>Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. <i>N Engl J Med</i>. 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27718784/pubmed\" target=\"_blank\" id=\"27718784\">27718784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Opdivo injection (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. <i>N Engl J Med</i>. 2015;372(4):320-330.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/253995524/pubmed\" target=\"_blank\" id=\"253995524\">253995524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin&rsquo;s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial. <i>Lancet Oncol</i>. 2016;17(9):1283-1294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nivolumab-pediatric-drug-information/abstract-text/27451390/pubmed\" target=\"_blank\" id=\"27451390\">27451390</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 115765 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26819875\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45691984\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F50189836\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50772821\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51131234\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51131235\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26827910\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991167\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988530\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26819876\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F26819874\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F27369132\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50189840\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F26822038\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50189837\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27560227\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27160903\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26702130\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26821961\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26736581\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26736578\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26821958\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50189841\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26822041\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F26822043\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26844488\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26732989\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/115765|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">Nivolumab: Drug information</a></li><li><a href=\"topic.htm?path=nivolumab-patient-drug-information\" class=\"drug drug_patient\">Nivolumab: Patient drug information</a></li></ul></div></div>","javascript":null}